ATE349533T1 - Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen - Google Patents

Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen

Info

Publication number
ATE349533T1
ATE349533T1 AT01952368T AT01952368T ATE349533T1 AT E349533 T1 ATE349533 T1 AT E349533T1 AT 01952368 T AT01952368 T AT 01952368T AT 01952368 T AT01952368 T AT 01952368T AT E349533 T1 ATE349533 T1 AT E349533T1
Authority
AT
Austria
Prior art keywords
polypeptides
diagnosis
treatment
composition
herpes simplex
Prior art date
Application number
AT01952368T
Other languages
English (en)
Inventor
Nancy A Hosken
Craig H Day
Davin C Dillon
Patrick Mcgowan
Paul R Sleath
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE349533T1 publication Critical patent/ATE349533T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01952368T 2000-06-29 2001-06-28 Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen ATE349533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21545800P 2000-06-29 2000-06-29
US27743801P 2001-03-20 2001-03-20

Publications (1)

Publication Number Publication Date
ATE349533T1 true ATE349533T1 (de) 2007-01-15

Family

ID=26910047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952368T ATE349533T1 (de) 2000-06-29 2001-06-28 Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen

Country Status (9)

Country Link
US (1) US6537555B2 (de)
EP (1) EP1297147B8 (de)
JP (1) JP2004501663A (de)
AT (1) ATE349533T1 (de)
AU (2) AU2001273128C1 (de)
CA (1) CA2411692A1 (de)
DE (1) DE60125537D1 (de)
NZ (1) NZ522734A (de)
WO (1) WO2002002131A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454750C (en) * 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20070184472A1 (en) * 2005-06-08 2007-08-09 Toagosei Co., Ltd Method of purifying environmental dna and method of efficiently screening for protein-encoding gene from environmental dna
US7763460B2 (en) * 2005-06-24 2010-07-27 Focus Diagnostics, Inc. Methods and compositions for detecting herpes simplex virus type 2
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
EP2421952B1 (de) 2009-04-20 2016-03-30 Galen Bio, Inc. Zusammensetzungen für die transfektion von biomolekülen in zellen
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP2013524806A (ja) 2010-04-23 2013-06-20 ゲノミク ビジョン 分子コーミングを用いるゲノムｄｎａ及び感染性ウイルスｄｎａの検出によるウイルス感染の診断
WO2012061637A2 (en) * 2010-11-03 2012-05-10 University Of Washington Hsv-1 epitopes and methods for using same
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
CA2826199A1 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
WO2016071925A2 (en) * 2014-11-05 2016-05-12 Indian Council Of Medical Research (Icmr) TITLE: INTEGRATION OF β-ACTIN GENE FOR SAMPLE QUALITY CHECK IN HSV-1 AND HSV-2 DIAGNOSTIC KIT
EP3519427A4 (de) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Verfahren und zusammensetzungen zur behandlung von herpes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232710B (de) * 1991-09-13 1994-10-21 American Cyanamid Co
GB9401333D0 (en) * 1994-01-25 1994-03-23 Medical Res Council Herpes virus pre-(viral dna replication) particles (preps)
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
CA2291010A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use

Also Published As

Publication number Publication date
US6537555B2 (en) 2003-03-25
AU2001273128B2 (en) 2006-03-16
CA2411692A1 (en) 2002-01-10
EP1297147A2 (de) 2003-04-02
NZ522734A (en) 2005-05-27
DE60125537D1 (de) 2007-02-08
JP2004501663A (ja) 2004-01-22
WO2002002131A2 (en) 2002-01-10
US20020090610A1 (en) 2002-07-11
WO2002002131A3 (en) 2003-01-03
EP1297147B1 (de) 2006-12-27
AU2001273128C1 (en) 2006-09-21
AU7312801A (en) 2002-01-14
EP1297147B8 (de) 2007-02-21

Similar Documents

Publication Publication Date Title
PL365951A1 (pl) Związki oraz sposoby leczenia i diagnozowania infekcji Chlamydia
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
NZ518917A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
DE69942426D1 (de) Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE389020T1 (de) Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
DE60125537D1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2003041560A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP0834567A3 (de) Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Babesia microti Infektion
WO2003020108A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection
WO2001085947A3 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection
FR2846658B1 (fr) Peptides pour la prevention, le diagnostic et le traitement de la leptospirose animale et/ou humaine.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties